NEW YORK (GenomeWeb News) – Inform Genomics said today it has reached a deal with Tesaro to evaluate the risk of chemotherapy-induced nausea and vomiting in patients.

Using Inform Genomics' bioinformatics and genomic platforms, Tesaro will assess the risk of nausea and vomiting in patients receiving certain "moderately" emetogenic chemotherapy regimens and standard antiemetic therapy, without an NK-1 receptor antagonist, Inform said.

Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: the Human Silencing Hub protein complex, and more.

Heads of various research funding agencies discuss how to encourage scientific breakthroughs, ScienceInsider reports.

The Kansas City Star examines issues surrounding newborn genome sequencing.

Researchers say their Research Resource Identifier citation format is catching on, Nature News reports.